De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Shattuck Labs Beheer

Beheer criteriumcontroles 3/4

De CEO Shattuck Labs' is Taylor Schreiber, benoemd in Jan2016, heeft een ambtstermijn van 8.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.03M, bestaande uit 50.8% salaris en 49.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 5.54% van de aandelen van het bedrijf, ter waarde $ 9.23M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3 jaar en 4.3 jaar.

Belangrijke informatie

Taylor Schreiber

Algemeen directeur

US$1.0m

Totale compensatie

Percentage CEO-salaris	50.8%
Dienstverband CEO	8.8yrs
Eigendom CEO	5.5%
Management gemiddelde ambtstermijn	3yrs
Gemiddelde ambtstermijn bestuur	4.3yrs

Recente managementupdates

Recent updates

Shattuck Labs, Inc. (NASDAQ:STTK) Just Reported And Analysts Have Been Cutting Their Estimates

Mar 18

Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Deliver On Growth Plans?

Feb 25

Will Shattuck Labs (NASDAQ:STTK) Spend Its Cash Wisely?

Nov 23

We Think Shattuck Labs (NASDAQ:STTK) Can Afford To Drive Business Growth

Aug 24

Shattuck Labs names Abhinav Shukla as chief technical officer

Jun 01

Shattuck Labs EPS beats by $0.11, beats on revenue

May 10

Here's Why We're Not Too Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation

May 07

Could The Shattuck Labs, Inc. (NASDAQ:STTK) Ownership Structure Tell Us Something Useful?

Mar 08

We're Hopeful That Shattuck Labs (NASDAQ:STTK) Will Use Its Cash Wisely

Jan 12

Analyse CEO-vergoeding

Hoe is Taylor Schreiber's beloning veranderd ten opzichte van Shattuck Labs's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$85m
Mar 31 2024	n/a	n/a	-US$85m
Dec 31 2023	US$1m	US$525k	-US$87m
Sep 30 2023	n/a	n/a	-US$95m
Jun 30 2023	n/a	n/a	-US$92m
Mar 31 2023	n/a	n/a	-US$98m
Dec 31 2022	US$1m	US$525k	-US$102m
Sep 30 2022	n/a	n/a	-US$69m
Jun 30 2022	n/a	n/a	-US$61m
Mar 31 2022	n/a	n/a	-US$58m
Dec 31 2021	US$744k	US$525k	-US$45m
Sep 30 2021	n/a	n/a	-US$65m
Jun 30 2021	n/a	n/a	-US$59m
Mar 31 2021	n/a	n/a	-US$42m
Dec 31 2020	US$2m	US$395k	-US$37m
Sep 30 2020	n/a	n/a	-US$32m
Jun 30 2020	n/a	n/a	-US$27m
Mar 31 2020	n/a	n/a	-US$26m
Dec 31 2019	US$419k	US$325k	-US$24m

Compensatie versus markt: De totale vergoeding ($USD 1.03M ) Taylor } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 677.23K ).

Compensatie versus inkomsten: De vergoeding van Taylor is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Taylor Schreiber (44 yo)

8.8yrs

Tenure

US$1,034,408

Compensatie

Dr. Taylor H. Schreiber, M.D., Ph D., is a Co-Founder of Shattuck Labs, Inc. since 2016 and also has been its Chief Executive Officer and Director since January 29, 2020 and 2017 respectively. Dr. Schreibe...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Taylor Schreiber	Co-Founder	8.8yrs	US$1.03m	5.54% $ 3.2m
Andrew Neill	Chief Financial Officer	4.3yrs	US$911.76k	0.16% $ 90.4k
Arunthathy Pandite	Chief Medical Officer	7.3yrs	US$1.01m	0.26% $ 151.4k
Abhinav Shukla	Chief Technical Officer	3.3yrs	US$1.20m	0.032% $ 18.6k
Conor Richardson	Vice President of Investor Relations	no data	geen gegevens	geen gegevens
Stephen Stout	General Counsel	2.8yrs	geen gegevens	0.15% $ 89.6k
Casi DeYoung	Chief Business Officer	4.8yrs	US$523.48k	0.026% $ 15.0k
Thomas Lampkin	Senior Vice President of Regulatory Affairs	2.8yrs	geen gegevens	geen gegevens
George Fromm	Chief Scientific Officer of ARC Platform	1.8yrs	geen gegevens	geen gegevens
Suresh Silva	Chief Scientific Officer of GADLEN Platform	1.8yrs	geen gegevens	geen gegevens
Kelli Collin	Senior Vice President of Quality	1.8yrs	geen gegevens	geen gegevens

3.0yrs

Gemiddelde duur

50yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van STTK wordt beschouwd als ervaren (gemiddelde ambtstermijn 3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Taylor Schreiber	Co-Founder	7.8yrs	US$1.03m	5.54% $ 3.2m
Neil Gibson	Independent Director	7.9yrs	US$136.46k	0.11% $ 64.3k
Andrew Pardoll	Member of Advisory Board	3.9yrs	geen gegevens	geen gegevens
Johann de Bono	Member of Advisory Board	no data	geen gegevens	geen gegevens
George Golumbeski	Independent Chairman of the Board	6.8yrs	US$154.20k	0.11% $ 66.6k
Helen Boudreau	Independent Director	4.3yrs	US$140.96k	0% $ 0
Ignacio Melero Bermejo	Member of Advisory Board	no data	geen gegevens	geen gegevens
Aurelien Marabelle	Member of Advisory Board	4.3yrs	geen gegevens	geen gegevens
Kurt Schalper	Member of Advisory Board	no data	geen gegevens	geen gegevens
Tyler Brous	Lead Independent Director	8.1yrs	US$138.46k	0.50% $ 290.5k
Carrie Brownstein	Independent Director	3yrs	US$124.96k	0% $ 0
Michael Lee	Independent Director	4.3yrs	US$124.96k	0% $ 0

4.3yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van STTK wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

Shattuck Labs Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Co-Founder recently bought US$50k worth of stock

Shattuck Labs, Inc. Announces Committee Appointments

Shattuck Labs, Inc., Annual General Meeting, Jun 07, 2024

General Counsel notifies of intention to sell stock

Insufficient new directors

Shattuck Labs, Inc. Announces Board Appointments

Recent updates

New minor risk - Market cap size

Consensus revenue estimates decrease by 19%, EPS upgraded

Will Shattuck Labs (NASDAQ:STTK) Spend Its Cash Wisely?

Price target decreased by 27% to US$8.00

Shattuck Labs, Inc. Announces Strategic Pipeline Prioritization to Include the Discontinuation of Its Clinical Program, SL-172154

Consensus revenue estimates increase by 23%

New major risk - Revenue and earnings growth

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Co-Founder recently bought US$50k worth of stock

Here's Why We're Watching Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation

Price target decreased by 7.9% to US$14.50

Shattuck Labs, Inc. Announces Committee Appointments

Consensus revenue estimates increase by 15%

Consensus revenue estimates increase by 159%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Shattuck Labs, Inc., Annual General Meeting, Jun 07, 2024

Consensus revenue estimates increase by 170%

General Counsel notifies of intention to sell stock

Insufficient new directors

Shattuck Labs, Inc. Announces Board Appointments

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Chief Financial Officer recently sold US$250k worth of stock

Chief Financial Officer notifies of intention to sell stock

Shattuck Labs, Inc. has filed a Follow-on Equity Offering in the amount of $30.000001 million.

New minor risk - Shareholder dilution

Shattuck Labs, Inc. has filed a Follow-on Equity Offering in the amount of $30.000001 million.

Price target increased by 21% to US$15.50

New major risk - Financial position

Consensus revenue estimates increase by 78%, EPS downgraded

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Shattuck Labs, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Shattuck Labs, Inc. to Present Topline Data from Phase 1 A/B Clinical Trial of Sl-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (Aml) and Higher-Mds) Patients At the American Society of Hematology (Ash) 2023 Annual Meeting

Consensus revenue estimates increase by 16%

Price target decreased by 21% to US$12.80

Consensus revenue estimates decrease by 11%

Consensus revenue estimates increase by 91%

New minor risk - Market cap size

Can Shattuck Labs (NASDAQ:STTK) Afford To Invest In Growth?

New minor risk - Share price stability

Consensus EPS estimates upgraded to US$2.03 loss

We're Keeping An Eye On Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Shattuck Labs, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Consensus forecasts updated

Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Invest In Growth?

Consensus revenue estimates increase by 264%

High number of new directors

Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.41 loss in 3Q 2021)

Shattuck Labs, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Second quarter 2022 earnings released: US$0.65 loss per share (vs US$0.56 loss in 2Q 2021)

Shattuck Labs GAAP EPS of -$0.65 misses by $0.06

We're Not Very Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate

Shattuck Labs, Inc.(NasdaqGS:STTK) dropped from Russell 2000 Growth Index

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Price target decreased to US$25.50

High number of new directors

Shattuck Labs, Inc., Annual General Meeting, Jun 07, 2022

Shattuck Labs Presents Preclinical Data At the 2022 American Association for Cancer Research (AACR) Annual Meeting

Consensus forecasts updated

Consensus forecasts updated

Shattuck Labs, Inc. (NASDAQ:STTK) Just Reported And Analysts Have Been Cutting Their Estimates

Price target decreased to US$39.00

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Deliver On Growth Plans?

Rosen Law Firm Files Securities Class Action Lawsuit Against Shattuck Labs, Inc

Lead Independent Director recently bought US$56k worth of stock

Will Shattuck Labs (NASDAQ:STTK) Spend Its Cash Wisely?

Chief Financial Officer exercised options to buy US$250k worth of stock.

Third quarter 2021 earnings released: US$0.41 loss per share (vs US$1.54 loss in 3Q 2020)